Mike Hollan

The Merck executive discusses how a personal tragedy has shaped her career and approach to promoting healthy choices.

Texas Biomed announced that research shows that a certain monoclonal antibody treatment could treat all variants of COVID-19, including past, present, and future strains.

Pharma companies are facing a higher number of incredibly destructive cyber-threats than ever before.

The Dandelion Health CEO discusses the collection and analysis of data in the digital world.

The company partnered with Marius Pharmaceuticals to offer access to Kyzatrex.

The “Do It For You & Them” campaign focuses on the impact that virus has on day-to-day lives.

As the second half of 2024 begins, an industry expert discusses how mergers and acquisitions are trending in the pharma industry.

The insurance company is offering the guidance in response to continued popularity of the drugs which are commonly used for weight-loss management.

Perspective Therapeutics’ CEO explains how this method can be used to determine how to target cancer cells without damaging other organs.

The product line includes vaccines, monoclonal antibodies, and antigens.

Pharmaceutical companies are seeing the benefits of being able to outsource entire functions through functional service providers.

Datapharm’s CEO discusses ways to improve access and accuracy for healthcare professionals and patients.

This makes Aetna the first major insurer to cover these types of services.

The novel lipid-in-oil delivery platform showed positive results across multiple disease states.

The two companies will work together to accelerate the drug discovery process for cancer treatments.

Rizzo discusses Veeva’s latest findings on how life sciences companies are utilizing this strategy to speed up uptake of new treatments.

The updated formulas should provide better protection against the currently circulating strains.

Gilad discusses the ways that this method can be used to treat various cancers without putting patients through the side effects of chemotherapy.

This agreement will allow the diagnostic information services company to expand its operations in Ohio.

Kelly discusses how the company takes a different approach to spinal cord injuries.

The pharmaceutical company worked with Coursera to develop the three-module course.

The acquisition will allow Lilly to add Morphic’s IBF treatment to its pipeline.

Culjat discusses FDA’s new draft framework on PDURS.

The test is the first of its kind and is available over the counter.

Astellas Pharma’s chief people officer and chief ethics & compliance officer discusses the unique ways he’s brought DE&I to the workplace.

Key approval signals progress in addressing immune-mediated inflammatory diseases.

New cardiovascular indication builds on treatment’s fast-growing legacy.

The campaign, More to Parkinson’s, will focus on providing education about Parkinson’s related hallucinations.

Heidi Capozzi previously served as chief people officer for McDonald’s.

According to the company, about one-third of the country is at risk for micronutrient deficiency.